Developer docs
API playgroundTry for free, no card

Search company profiles

Oncologica

Full company profile

uuid000lcpd

Namestring
Oncologica
Legal namestring
Oncologica UK Limited
Websiteurl
oncologica.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Oncologica UK Limited is a Cambridge-based precision oncology laboratory founded in 2014 by Prof Gareth H Williams and Dr Marco Loddo, operating as one of the first clinically approved genomic profiling laboratories in Europe. The company sells three core diagnostic tests: Oncofocus, a 505-gene DNA/RNA sequencing panel that links actionable tumor mutations to 700 targeted therapies and clinical trials; Immunofocus, a suite of tests for immunotherapy response prediction including tumor mutational burden (TMB), PD-L1 expression, and mismatch repair (MMR) gene analysis; and ProstateFocus, an AI-driven non-invasive urine liquid biopsy test for early prostate cancer detection reporting AUC of 0.93 versus 0.66 for standard PSA. Underlying technology combines next-generation sequencing with semiconductor sequencing platforms (ThermoFisher TaqPath and Ion AmpliSeq) and proprietary cell cycle engine analysis methodology protected by international patents and 40+ peer-reviewed publications. The company also runs a contract research organization (CRO) offering biomarker discovery and companion diagnostics for pharmaceutical clients, and from 2020 to 2022 scaled a high-volume COVID-19 PCR testing and genomic sequencing business that delivered up to 40,000 tests per day as the largest surge laboratory in the UK under a DHSC/UKHSA contract.

Oncologica monetizes precision oncology tests through clinician- and hospital-ordered B2B sales at approximately £2,000 per test (covered by all leading UK health insurers, with direct-pay option), supplemented by CRO professional services revenue, government COVID-19 testing contracts, and a new direct-to-consumer channel for ProstateFocus with a subscription or per-test home urine kit model. The customer base spans NHS hospitals and oncologists (primary), cancer patients (primary persona), pharmaceutical and biotech companies (CRO), the UK Government (COVID), and corporate/institutional clients. Distribution combines clinician-initiated test ordering with worldwide sample shipment, an e-commerce storefront at covid-19.oncologica.com, and a proprietary IT platform with mobile app, API, built-in CRM, and automated results reporting load-tested to 50,000 samples per day and 45,000 concurrent users.

The business is founder-led and privately held, with no disclosed external funding rounds, parent company, or institutional investors. Notable strategic relationships include an AstraZeneca collaboration on the VENTANA PD-L1 (SP263) Assay companion diagnostic (2018), a Christie Hospital Manchester referral pipeline for clinical trial enrollment including the PROCLAIM-CX-072 trial, and an IQN Path expert guidelines collaboration. Headcount is in the 11-50 range and revenue is not publicly disclosed; the company is recognized via BBC Tomorrow's World Health Innovation Award (2000), UK Medical Futures Innovation Award (2008), and shortlisting for the PMI Special Covid-19 UK Response Project Award (2020).

Short descriptiontext

Oncologica is a UK-based precision oncology laboratory offering genomic profiling tests (Oncofocus, Immunofocus) and an AI-driven urine liquid biopsy (ProstateFocus) to match cancer patients with targeted therapies and enable early prostate cancer detection for clinicians, hospitals, insurers, and pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology testing, genomic profiling services, cancer genetic diagnostics, liquid biopsy screening, contract research organization
Industry4 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Precision Oncology Genetic Testing Services
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Precision Oncology Testing Services
TypeOne Time License
Description

Revenue generated from comprehensive genomic profiling tests (Oncofocus, Immunofocus) that sequence tumor DNA/RNA to match patients with targeted therapies. Tests are ordered by oncologists for patients with solid tumors. The test is covered by all leading health insurers and can also be paid for directly by patients.

oncologica.com
2Contract Research Services
TypeProfessional Services
Description

Oncologica functions as a Contract Research Organization (CRO) providing genomic research services, biomarker discovery, and companion diagnostics development for pharmaceutical and biotech companies supporting drug development programs.

oncologica.com
3COVID-19 Testing Services
TypeOne Time License
Description

High-volume PCR testing and genomic sequencing services for international travellers, private companies, educational institutions, healthcare facilities, and transport networks. Services include test kits, processing, and variant sequencing under government contracts.

oncologica.com
4Early Cancer Detection Screening
TypeSubscription Recurring
Description

ProstateFocus AI-driven prostate cancer screening test offered as a non-invasive home urine test. Provides subscription or per-test revenue model for early cancer detection services.

oncologica.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Pricing details4 tiers
1Oncofocus Tumor Genetic Analysis - Standard Test
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Covered by all leading health insurers. Results available 15 working days from sample receipt. Includes free standard worldwide sample shipment and hospital return. Phone, chat and email support included.

oncologica.com
2Oncofocus Direct Patient Purchase
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Approximately £2000 for direct patient purchase, as evidenced by patient testimonial (Karan Jensen case). Includes biopsy collection coordination with treating hospital.

oncologica.com
3ProstateFocus Early Detection Test
ModelSubscriptionBilling cadencePay-as-you-go
Notes

Non-invasive home urine screening test for prostate cancer using AI-driven analysis. Available as a direct-to-consumer product.

oncologica.com
4COVID-19 PCR Testing
ModelUsage-basedBilling cadencePay-as-you-go
Notes

High-volume testing at 40,000 tests/day capacity with 12-hour turnaround time. Available for Pre-travel Fit to Fly, Day 2 Green list, Day 2 Day 8 Amber list arrivals, and Day 5 Test to Release certificates.

oncologica.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Oncologica operates a clinically approved cancer genetics laboratory providing precision oncology testing services. Its core offerings are genomic profiling tests (Oncofocus, Immunofocus, ProstateFocus) that sequence tumor DNA/RNA from biopsy or liquid biopsy samples to identify actionable mutations and match patients with targeted therapies, immunotherapies, or clinical trials. The company also offers contract research services for pharmaceutical biomarker and companion diagnostics programs, and operates high-throughput COVID-19 PCR testing and genomic sequencing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • AUC 0.93 prostate cancer detection accuracy vs 0.66 for PSA standard
+4 more records
Product overview1 text field

Oncologica is a precision oncology company offering a suite of diagnostic tests centered on advanced genomic profiling. The core offerings include Oncofocus (a comprehensive 505-gene tumor DNA/RNA sequencing panel linking actionable mutations to 700 targeted therapies), Immunofocus (immunotherapy response prediction via TMB, PD-L1, and MMR testing), and ProstateFocus (AI-driven urine liquid biopsy for early prostate cancer detection). ProstateFocus features a proprietary IT platform with API interface for B2B connections to third-party systems and LIMS, dedicated mobile app for patients, built-in CRM, and automated reporting. The company also provides genomic research contract services and COVID-19 testing via the Coronafocus platform.

Product and service5 records
1Oncofocus
CategoryPrecision oncology tumor genomic profiling test
Description

Comprehensive precision oncology test that sequences DNA and RNA of a patient's tumor to generate a personalized genetic profile, targeting 505 genes with actionable mutations linked to 700 anti-cancer targeted therapies or treatments in clinical trials. Results available within 15 working days. Covered by all leading health insurers; direct patient purchase available for approximately £2,000. Targeted at oncologists and cancer patients with solid tumors seeking personalized treatment options.

2Immunofocus
CategoryImmunotherapy biomarker testing
Description

Suite of genetic tests designed to assess immunotherapy response, including TMB Test (measures tumor mutational burden and neoantigens), PD-L1 Test (measures PD-L1 protein expression levels), and MMR Test (analyzes mismatch repair genes MLH1, MSH2, MSH6, and PMS2 to identify DNA repair defects). Used by oncologists to identify patients likely to respond to immunotherapy and to reduce exposure to ineffective treatment.

3ProstateFocus
CategoryAI-driven liquid biopsy cancer screening test
Description

AI-driven, non-invasive urine liquid biopsy home screening test for early prostate cancer detection. Powered by an AI-generated algorithm analyzing cell cycle engine and linked oncogenic signaling networks to identify early-stage prostate cancer with AUC 0.93 accuracy vs 0.66 for PSA. Includes a proprietary IT platform with API interface for B2B integration, dedicated mobile app, built-in CRM, and automated reporting. Sold direct-to-consumer via subscription or per-test pricing.

4Genomic Research Services
CategoryContract research services (CRO)
Description

Contract research services providing high-quality genetic testing and bioinformatics solutions for biomarker and drug development programs. Supports theranostic programs at all stages of cancer drug development from discovery through preclinical development to clinical trials. Targeted at pharmaceutical and biotech companies.

5COVID-19 Testing Services (Coronafocus)
CategoryViral PCR testing and genomic sequencing
Description

High-volume PCR testing and SARS-CoV-2 genomic sequencing services, including the Coronafocus integrated Test and Sequence platform. Uses semiconductor sequencing technology with >99% coverage of the viral genome to identify variants of concern. Capacity of up to 40,000 tests per day with 12-hour turnaround. Served international travellers, private companies, educational institutions, healthcare facilities, transport networks, and the UK DHSC/UKHSA under government contract.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeOthersAnnounced on2020-05-01
Description

Contracted as part of the volunteer Covid-19 Testing Network to support the DHSC Covid-19 National Testing Programme covering care homes, local authorities, schools, symptomatic testing, and international arrivals. Delivered up to 40k tests per day as the largest surge laboratory in UK.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Expert opinion collaboration on integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumors. Dr Marco Loddo contributed to expert guidelines publication.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Collaboration on VENTANA PD-L1 (SP263) Assay study involving internationally recognized pathologists to assess the performance of PD-L1 testing as a companion diagnostic for anti-PD-L1 immunotherapy in lung cancer. Study completed and findings published in Journal of Thoracic Oncology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Patient referral partnership where cancer patients identified through Oncofocus testing as potential immunotherapy responders are enrolled in clinical trials at Christie Hospital, including PROCLAIM-CX-072 trial investigating PD-L1 targeting drugs.

Strategic tierCoreTypeTechnology or Integration
Description

Using TaqPath COVID-19 CE-IVD RT-PCR Kit (multiplex assay) for COVID testing and Ion AmpliSeq SARS-CoV-2 Research Panel for sequencing. Semiconductor sequencing technology enables >99% coverage of viral genome for precise variant identification.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Guardant Health is a leader in liquid biopsy and ctDNA-based oncology testing (Guardant360, Shield), making it a direct peer for Oncologica's ProstateFocus liquid biopsy and broader precision oncology testing services.

TypeDirect peer
Description

Personalis provides comprehensive genomic profiling (NeXT Personal) and supports pharma biomarker programmes — a direct peer to Oncologica's Oncofocus/Immunofocus tests and its CRO/companion diagnostic services.

TypeDirect peer
Description

Foundation Medicine provides comprehensive genomic profiling of tumours (FoundationOne CDx) linking mutations to targeted therapies — directly comparable to Oncologica's Oncofocus 505-gene panel and Immunofocus assays.

TypeEmerging player
Description

Natera's Signatera MRD test and oncology liquid biopsy franchise overlaps with Oncologica's liquid biopsy/ctDNA-style approaches and broader precision oncology testing portfolio.

TypeDirect peer
Description

Caris provides comprehensive molecular profiling (MI Profile) and AI-driven analytics for oncology treatment selection, directly comparable to Oncologica's theranostic profiling and CRO biomarker services.

6Tempus Labs
TypeDirect peer
Description

Tempus offers NGS-based oncology profiling and AI-driven clinical decision support, comparable to Oncologica's combination of Oncofocus genomic profiling and ProstateFocus AI-driven early detection.

TypeDirect peer
Description

Myriad offers molecular diagnostics across oncology (BRACAnalysis, myChoice HRD) and provides companion diagnostic services for pharma, comparable to Oncologica's Immunofocus (MMR/PD-L1) and CRO biomarker work.

TypeDirect peer
Description

Exact Sciences (including Genomic Health's Oncotype DX) provides genomic testing for cancer treatment selection and screening — comparable to Oncologica's Oncofocus theranostic tests and ProstateFocus screening.

TypeDirect peer
Description

NeoGenomics operates a global oncology-focused clinical laboratory offering comprehensive genomic profiling, immuno-oncology testing, and pharma services — directly comparable in service portfolio to Oncologica's clinical and CRO business.

TypeBroad incumbent
Description

Bio-Techne's diagnostics segment (including ExoDx and protein biomarker assays) provides oncology diagnostic tools and reagents, making it a broader incumbent comparable to Oncologica's biomarker discovery and molecular diagnostic activities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncologica

Precision Oncology Genetic Testing Servicesoncologica.com

Oncologica is a UK-based precision oncology laboratory offering genomic profiling tests (Oncofocus, Immunofocus) and an AI-driven urine liquid biopsy (ProstateFocus) to match cancer patients with targeted therapies and enable early prostate cancer detection for clinicians, hospitals, insurers, and pharma.

What Oncologica does

Oncologica UK Limited is a Cambridge-based precision oncology laboratory founded in 2014 by Prof Gareth H Williams and Dr Marco Loddo, operating as one of the first clinically approved genomic profiling laboratories in Europe. The company sells three core diagnostic tests: Oncofocus, a 505-gene DNA/RNA sequencing panel that links actionable tumor mutations to 700 targeted therapies and clinical trials; Immunofocus, a suite of tests for immunotherapy response prediction including tumor mutational burden (TMB), PD-L1 expression, and mismatch repair (MMR) gene analysis; and ProstateFocus, an AI-driven non-invasive urine liquid biopsy test for early prostate cancer detection reporting AUC of 0.93 versus 0.66 for standard PSA. Underlying technology combines next-generation sequencing with semiconductor sequencing platforms (ThermoFisher TaqPath and Ion AmpliSeq) and proprietary cell cycle engine analysis methodology protected by international patents and 40+ peer-reviewed publications. The company also runs a contract research organization (CRO) offering biomarker discovery and companion diagnostics for pharmaceutical clients, and from 2020 to 2022 scaled a high-volume COVID-19 PCR testing and genomic sequencing business that delivered up to 40,000 tests per day as the largest surge laboratory in the UK under a DHSC/UKHSA contract.

Oncologica monetizes precision oncology tests through clinician- and hospital-ordered B2B sales at approximately £2,000 per test (covered by all leading UK health insurers, with direct-pay option), supplemented by CRO professional services revenue, government COVID-19 testing contracts, and a new direct-to-consumer channel for ProstateFocus with a subscription or per-test home urine kit model. The customer base spans NHS hospitals and oncologists (primary), cancer patients (primary persona), pharmaceutical and biotech companies (CRO), the UK Government (COVID), and corporate/institutional clients. Distribution combines clinician-initiated test ordering with worldwide sample shipment, an e-commerce storefront at covid-19.oncologica.com, and a proprietary IT platform with mobile app, API, built-in CRM, and automated results reporting load-tested to 50,000 samples per day and 45,000 concurrent users.

The business is founder-led and privately held, with no disclosed external funding rounds, parent company, or institutional investors. Notable strategic relationships include an AstraZeneca collaboration on the VENTANA PD-L1 (SP263) Assay companion diagnostic (2018), a Christie Hospital Manchester referral pipeline for clinical trial enrollment including the PROCLAIM-CX-072 trial, and an IQN Path expert guidelines collaboration. Headcount is in the 11-50 range and revenue is not publicly disclosed; the company is recognized via BBC Tomorrow's World Health Innovation Award (2000), UK Medical Futures Innovation Award (2008), and shortlisting for the PMI Special Covid-19 UK Response Project Award (2020).

Oncologica firmographics

Firmographics
Name
Oncologica
Legal name
Oncologica UK Limited
Website
https://oncologica.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Oncologica is a UK-based precision oncology laboratory offering genomic profiling tests (Oncofocus, Immunofocus) and an AI-driven urine liquid biopsy (ProstateFocus) to match cancer patients with targeted therapies and enable early prostate cancer detection for clinicians, hospitals, insurers, and pharma.
Ownership category
akta.pro rank

Oncologica industry classification

Industry
Product category
Precision Oncology Genetic Testing Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services

Keywords

  • Precision oncology testing
  • Genomic profiling services
  • Cancer genetic diagnostics
  • Liquid biopsy screening
  • Contract research organization

Where Oncologica is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Oncologica business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Precision Oncology Testing Services: Revenue generated from comprehensive genomic profiling tests (Oncofocus, Immunofocus) that sequence tumor DNA/RNA to match patients with targeted therapies. Tests are ordered by oncologists for patients with solid tumors. The test is covered by all leading health insurers and can also be paid for directly by patients.
  2. Contract Research Services: Oncologica functions as a Contract Research Organization (CRO) providing genomic research services, biomarker discovery, and companion diagnostics development for pharmaceutical and biotech companies supporting drug development programs.
  3. COVID-19 Testing Services: High-volume PCR testing and genomic sequencing services for international travellers, private companies, educational institutions, healthcare facilities, and transport networks. Services include test kits, processing, and variant sequencing under government contracts.
  4. Early Cancer Detection Screening: ProstateFocus AI-driven prostate cancer screening test offered as a non-invasive home urine test. Provides subscription or per-test revenue model for early cancer detection services.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goOncofocus Tumor Genetic Analysis - Standard Test
One time/ perpetual licensePay-as-you-goOncofocus Direct Patient Purchase
SubscriptionPay-as-you-goProstateFocus Early Detection Test
Usage-basedPay-as-you-goCOVID-19 PCR Testing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Oncologica product offering

Product offering

Core offering

Oncologica operates a clinically approved cancer genetics laboratory providing precision oncology testing services. Its core offerings are genomic profiling tests (Oncofocus, Immunofocus, ProstateFocus) that sequence tumor DNA/RNA from biopsy or liquid biopsy samples to identify actionable mutations and match patients with targeted therapies, immunotherapies, or clinical trials. The company also offers contract research services for pharmaceutical biomarker and companion diagnostics programs, and operates high-throughput COVID-19 PCR testing and genomic sequencing.

Product overview

Oncologica is a precision oncology company offering a suite of diagnostic tests centered on advanced genomic profiling. The core offerings include Oncofocus (a comprehensive 505-gene tumor DNA/RNA sequencing panel linking actionable mutations to 700 targeted therapies), Immunofocus (immunotherapy response prediction via TMB, PD-L1, and MMR testing), and ProstateFocus (AI-driven urine liquid biopsy for early prostate cancer detection). ProstateFocus features a proprietary IT platform with API interface for B2B connections to third-party systems and LIMS, dedicated mobile app for patients, built-in CRM, and automated reporting. The company also provides genomic research contract services and COVID-19 testing via the Coronafocus platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • Oncofocus Comprehensive precision oncology test that sequences DNA and RNA of a patient's tumor to generate a personalized genetic profile, targeting 505 genes with actionable mutations linked to 700 anti-cancer targeted therapies or treatments in clinical trials. Results available within 15 working days. Covered by all leading health insurers; direct patient purchase available for approximately £2,000. Targeted at oncologists and cancer patients with solid tumors seeking personalized treatment options.
  • Immunofocus Suite of genetic tests designed to assess immunotherapy response, including TMB Test (measures tumor mutational burden and neoantigens), PD-L1 Test (measures PD-L1 protein expression levels), and MMR Test (analyzes mismatch repair genes MLH1, MSH2, MSH6, and PMS2 to identify DNA repair defects). Used by oncologists to identify patients likely to respond to immunotherapy and to reduce exposure to ineffective treatment.
  • ProstateFocus AI-driven, non-invasive urine liquid biopsy home screening test for early prostate cancer detection. Powered by an AI-generated algorithm analyzing cell cycle engine and linked oncogenic signaling networks to identify early-stage prostate cancer with AUC 0.93 accuracy vs 0.66 for PSA. Includes a proprietary IT platform with API interface for B2B integration, dedicated mobile app, built-in CRM, and automated reporting. Sold direct-to-consumer via subscription or per-test pricing.
  • Genomic Research Services Contract research services providing high-quality genetic testing and bioinformatics solutions for biomarker and drug development programs. Supports theranostic programs at all stages of cancer drug development from discovery through preclinical development to clinical trials. Targeted at pharmaceutical and biotech companies.
  • COVID-19 Testing Services (Coronafocus) High-volume PCR testing and SARS-CoV-2 genomic sequencing services, including the Coronafocus integrated Test and Sequence platform. Uses semiconductor sequencing technology with >99% coverage of the viral genome to identify variants of concern. Capacity of up to 40,000 tests per day with 12-hour turnaround. Served international travellers, private companies, educational institutions, healthcare facilities, transport networks, and the UK DHSC/UKHSA under government contract.

Quantifiable outcome

  • AUC 0.93 prostate cancer detection accuracy vs 0.66 for PSA standard
  • +4 more outcomes

Companies that use Oncologica

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Oncologica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature9 records

Oncologica partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • UK Government (DHSC/UKHSA)coreOthers · 1 May 2020Contracted as part of the volunteer Covid-19 Testing Network to support the DHSC Covid-19 National Testing Programme covering care homes, local authorities, schools, symptomatic testing, and international arrivals. Delivered up to 40k tests per day as the largest surge laboratory in UK.
  • IQN Path ASBLminorStrategic or Co-development Partner · 1 January 2020Expert opinion collaboration on integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumors. Dr Marco Loddo contributed to expert guidelines publication.
  • AstraZenecacoreStrategic or Co-development Partner · 1 January 2018Collaboration on VENTANA PD-L1 (SP263) Assay study involving internationally recognized pathologists to assess the performance of PD-L1 testing as a companion diagnostic for anti-PD-L1 immunotherapy in lung cancer. Study completed and findings published in Journal of Thoracic Oncology.
  • Christie Hospital ManchestercoreStrategic or Co-development PartnerPatient referral partnership where cancer patients identified through Oncofocus testing as potential immunotherapy responders are enrolled in clinical trials at Christie Hospital, including PROCLAIM-CX-072 trial investigating PD-L1 targeting drugs.
  • ThermoFisher ScientificcoreTechnology or IntegrationUsing TaqPath COVID-19 CE-IVD RT-PCR Kit (multiplex assay) for COVID testing and Ion AmpliSeq SARS-CoV-2 Research Panel for sequencing. Semiconductor sequencing technology enables >99% coverage of viral genome for precise variant identification.

Scale indicators11 records

Recent moves5 records

Expansion highlights6 records

Oncologica competitors and assessment

Company assessment

Direct peers

  • Guardant Health: Guardant Health is a leader in liquid biopsy and ctDNA-based oncology testing (Guardant360, Shield), making it a direct peer for Oncologica's ProstateFocus liquid biopsy and broader precision oncology testing services.
  • Personalis: Personalis provides comprehensive genomic profiling (NeXT Personal) and supports pharma biomarker programmes — a direct peer to Oncologica's Oncofocus/Immunofocus tests and its CRO/companion diagnostic services.
  • Foundation Medicine: Foundation Medicine provides comprehensive genomic profiling of tumours (FoundationOne CDx) linking mutations to targeted therapies — directly comparable to Oncologica's Oncofocus 505-gene panel and Immunofocus assays.
  • Caris Life Sciences: Caris provides comprehensive molecular profiling (MI Profile) and AI-driven analytics for oncology treatment selection, directly comparable to Oncologica's theranostic profiling and CRO biomarker services.
  • Tempus Labs: Tempus offers NGS-based oncology profiling and AI-driven clinical decision support, comparable to Oncologica's combination of Oncofocus genomic profiling and ProstateFocus AI-driven early detection.
  • Myriad Genetics: Myriad offers molecular diagnostics across oncology (BRACAnalysis, myChoice HRD) and provides companion diagnostic services for pharma, comparable to Oncologica's Immunofocus (MMR/PD-L1) and CRO biomarker work.
  • Exact Sciences: Exact Sciences (including Genomic Health's Oncotype DX) provides genomic testing for cancer treatment selection and screening — comparable to Oncologica's Oncofocus theranostic tests and ProstateFocus screening.
  • NeoGenomics: NeoGenomics operates a global oncology-focused clinical laboratory offering comprehensive genomic profiling, immuno-oncology testing, and pharma services — directly comparable in service portfolio to Oncologica's clinical and CRO business.

Emerging players

  • Natera: Natera's Signatera MRD test and oncology liquid biopsy franchise overlaps with Oncologica's liquid biopsy/ctDNA-style approaches and broader precision oncology testing portfolio.

Broad incumbents

  • Bio-Techne: Bio-Techne's diagnostics segment (including ExoDx and protein biomarker assays) provides oncology diagnostic tools and reagents, making it a broader incumbent comparable to Oncologica's biomarker discovery and molecular diagnostic activities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Oncologica social profiles

Digital presence

Oncologica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncologica leadership team

Management profile

Number of profiles

Profiles9 records

Oncologica funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncologica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncologica

What does Oncologica do?

Oncologica operates a clinically approved cancer genetics laboratory providing precision oncology testing services. Its core offerings are genomic profiling tests (Oncofocus, Immunofocus, ProstateFocus) that sequence tumor DNA/RNA from biopsy or liquid biopsy samples to identify actionable mutations and match patients with targeted therapies, immunotherapies, or clinical trials. The company also offers contract research services for pharmaceutical biomarker and companion diagnostics programs, and operates high-throughput COVID-19 PCR testing and genomic sequencing.

Is Oncologica a public or private company?

Oncologica is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Oncologica founded?

Oncologica was founded in 2014. It employs 11 to 50 people.

Where is Oncologica based?

Oncologica is headquartered in Cambridge, United States, in the North America region.

How does Oncologica make money?

Four revenue lines are on record. Precision Oncology Testing Services are the primary driver. The others are contract Research Services, COVID-19 Testing Services and early Cancer Detection Screening.

Who are Oncologica's main competitors?

Direct peers on record are Guardant Health, Personalis, Foundation Medicine, Caris Life Sciences, Tempus Labs, Myriad Genetics, Exact Sciences and NeoGenomics. Natera is listed as an emerging player. Bio-Techne is listed as a broad incumbent.

Does Oncologica have an API?

No public API is recorded for Oncologica.

What industry is Oncologica in?

Oncologica's product category is Precision Oncology Genetic Testing Services. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals